Antagoniste IL-1R

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Primary TargetTIR domain-mediated MyD88/IL1-RI interaction

Reversible: no

Product does not compete with ATP.

Cell permeable: yes

General description

A cell-permeable, end protected L-valyl derivative modeled on the MyD88-binding sequence of the TIR (Toll/IL-1R/resistance) domain BB-loop of IL-1RI (type I IL-1 receptor). It specifically inhibits TIR domain-mediated MyD88/IL1-RI interaction without affecting TLR4/MyD88 interaction. It was used successfully to reduce IL-1β-induced fever in mice in vivo and to attenuate IL-1β-induced, but not LPS-induced, activation of MAP kinase signaling cascades in murine lymphocytes and EL4 thymoma cells in vitro.

A cell-permeable, end protected L-valyl derivative of the MyD88-binding sequence of the TIR (Toll/IL-1R/resistance) domain BB-loop of IL-1RI (type I IL-1 receptor). It specifically inhibits TIR domain-mediated MyD88/IL1-RI interaction without affecting TLR4/MyD88 interaction. It was used successfully to reduce IL-1β-induced fever in mice in vivo and to attenuate IL-1β-induced, but not LPS-induced, activation of MAP kinase signaling cascades in murine lymphocytes and EL4 thymoma cells in vitro.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Bartfai, T., et al. 2003. Proc. Natl. Acad. Sci. USA100, 7971.

Packaging

Packaged under inert gas

10, 25 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)